Clinical Trials Browser

Phase 2 × Breast Neoplasms × entinostat × Clear all

NCT07492394 2026-04-02

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT07441486 2026-03-02

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Phase 2 Recruiting

Breast Neoplasms

NCT07235618 2025-11-19

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Phase 2 Completed

58 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00828854 2022-06-30

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Phase 2 Completed

27 enrolled 13 charts

Breast Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00676663 2022-05-11

ENCORE301

Phase 2 Completed

130 enrolled 18 charts

Breast Neoplasms, Mammary Neoplasms, Animal

NCT01234532 2022-05-03

0927GCC

Phase 2 Terminated

5 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02115594 2014-10-08

ENCORE305

Phase 2 Withdrawn

Breast Neoplasms